文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

帕博利珠单抗治疗儿童晚期黑色素瘤或PD-L1阳性晚期复发/难治性实体瘤或淋巴瘤:KEYNOTE-051 1-2期试验中期分析

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
PubMed 文献 · Lancet Oncol · 2019-12-04

KEYNOTE-051是一项开放标签、单臂1-2期试验的中期分析,纳入6月龄至17岁、PD-L1阳性复发或难治性实体瘤或淋巴瘤或黑色素瘤患儿,确定帕博利珠单抗2 mg/kg每3周为2期推荐剂量。

要点

  • 儿童2期推荐剂量为2 mg/kg每3周,未观察到剂量限制性毒性。

核心结论

  • 帕博利珠单抗在儿童复发/难治经典型霍奇金淋巴瘤中耐受良好且显示鼓舞人心的抗肿瘤活性。
  • 帕博利珠单抗在大多数儿童肿瘤类型中抗肿瘤活性低,仅少数罕见PD-L1阳性肿瘤类型观察到缓解。
  • PD-L1表达单独不足以作为筛选可能对PD-1检查点抑制剂应答的儿童患者的生物标志物。

研究设计与样本

  • KEYNOTE-051为正在进行的开放标签、单臂1-2期试验,期中分析数据截止2018年9月3日。
  • 研究在澳大利亚、巴西、加拿大、法国、德国、以色列、意大利、韩国、瑞典、英国和美国的30家医院入组6月龄至17岁患者。
  • 入组条件为黑色素瘤或中心确认的PD-L1阳性复发/难治性实体瘤或淋巴瘤,Lansky Play/Karnofsky体能状态评分≥50。
  • 患者接受帕博利珠单抗初始剂量2 mg/kg每3周静脉给药,通过药代动力学和剂量限制性毒性确定2期推荐剂量。
  • 154例至少接受一剂帕博利珠单抗的患者纳入安全性和疗效评估。

主要发现

  • 筛查863例患者,796例肿瘤可评估PD-L1表达,其中278例(35%)为PD-L1阳性,最终入组155例合格患者。
  • 1期未报告剂量限制性毒性,帕博利珠单抗血浆浓度与成人既往报道一致,2期推荐剂量确定为2 mg/kg每3周。
  • 154例治疗患者中69例(45%)发生3-5级不良事件,最常见为贫血14例(9%)和淋巴细胞计数降低9例(6%)。
  • 13例(8%)发生3-5级治疗相关不良事件,最常见为淋巴细胞计数降低3例(2%)和贫血2例(1%)。

关键数值与推荐

  • 14例(9%)发生严重治疗相关不良事件,最常见为发热4例(3%),高血压和胸腔积液各2例(1%)。
  • 4例(3%)因治疗相关不良事件终止治疗,2例(1%)死亡(1例因肺水肿,1例因胸腔积液和肺炎)。
  • 缓解评估采用RECIST 1.1版或国际神经母细胞瘤缓解标准。

临床怎么用

  • 儿童患者帕博利珠单抗可采用2 mg/kg每3周方案,该剂量为2期推荐剂量且未观察到剂量限制性毒性。
  • 复发/难治经典型霍奇金淋巴瘤儿童患者可考虑帕博利珠单抗治疗,其客观缓解率与成人经验一致。
  • 多数儿童实体瘤和其他淋巴瘤不应仅依据PD-L1阳性选择帕博利珠单抗,因客观缓解率低。

局限性

  • 本报告为期中分析,最终结果预计2022年9月报告,可能延长。
  • 经典型霍奇金淋巴瘤队列的单独报告为事后决定。
  • 研究为单臂设计,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab is approved for the treatment of advanced cancer in adults; however, no information is available on safety and efficacy in paediatric patients. We aimed to establish the recommended phase 2 dose of pembrolizumab and its safety and antitumour activity in advanced paediatric cancer. METHODS: KEYNOTE-051 is an ongoing phase 1-2 open-label trial. In this interim analysis, children aged 6 months to 17 years were recruited at 30 hospitals located in Australia, Brazil, Canada, France, Germany, Israel, Italy, South Korea, Sweden, the UK, and the USA. Patients with melanoma or a centrally confirmed, PD-L1-positive, relapsed or refractory solid tumour or lymphoma, and a Lansky Play/Karnofsky Performance status score of 50 or higher, received intravenous pembrolizumab at an initial dose of 2 mg/kg every 3 weeks. Pharmacokinetics and dose-limiting toxicities were used to establish the recommended phase 2 dose, and the safety and antitumour activity of this dose were assessed. Primary endpoints were determination of dose-limiting toxicities at the maximum administered dose, safety and tolerability, and the proportion of patients with objective response to pembrolizumab for each tumour type according to the Response Evaluation Criteria in Solid Tumours version 1.1 or the International Neuroblastoma Response Criteria. Safety and efficacy were assessed in all treated patients who received at least one dose of pembrolizumab. Separate reporting of the cohort of patients with relapsed or refractory classical Hodgkin lymphoma was a post-hoc decision. The data cutoff for this interim analysis was Sept 3, 2018. This trial is still enrolling patients and is registered with ClinicalTrials.gov, number NCT02332668. FINDINGS: Of 863 patients screened between March 23, 2015, and Sept 3, 2018, 796 had tumours that were evaluable for PD-L1 expression (278 [35%] were PD-L1-positive); 155 eligible patients were enrolled and 154 had at least one dose of pembrolizumab. The median age of the enrolled patients was 13 years (IQR 8-15). Median follow-up was 8·6 months (IQR 2·5-16·4). No dose-limiting toxicities were reported in phase 1, and pembrolizumab plasma concentrations were consistent with those previously reported in adults; the recommended phase 2 dose was therefore established as 2 mg/kg every 3 weeks. Of the 154 patients treated, 69 (45%) experienced grade 3-5 adverse events, most commonly anaemia in 14 (9%) patients and decreased lymphocyte count in nine (6%) patients. 13 (8%) of the 154 patients had grade 3-5 treatment-related adverse events, most commonly decreased lymphocyte count in three (2%) patients and anaemia in two (1%) patients. 14 (9%) patients had serious treatment-related adverse events, most commonly pyrexia (four [3%]), and hypertension and pleural effusion (two [1%] each). Four patients (3%) discontinued treatment because of treatment-related adverse events, and two (1%) died (one due to pulmonary oedema and one due to pleural effusion and pneumonitis). Of 15 patients with relapsed or refractory Hodgkin lymphoma, two had complete and seven had partial responses; thus, nine patients achieved an objective response (60·0%; 95% CI 32·3-83·7). Of 136 patients with solid tumours and other lymphomas, eight had partial responses (two patients each with adrenocortical carcinoma and mesothelioma, and one patient each with malignant ganglioglioma, epithelioid sarcoma, lymphoepithelial carcinoma, and malignant rhabdoid tumour); the proportion of patients with an objective response was 5·9% (95% CI 2·6-11·3). INTERPRETATION: Pembrolizumab was well tolerated and showed encouraging antitumour activity in paediatric patients with relapsed or refractory Hodgkin lymphoma, consistent with experience in adult patients. Pembrolizumab had low antitumour activity in the majority of paediatric tumour types, and responses were observed in only a few rare PD-L1-positive tumour types, suggesting that PD-L1 expression alone is not sufficient as a biomarker for the selection of paediatric patients who are likely to respond to PD-1 checkpoint inhibitors. Final results of KEYNOTE-051, expected by September, 2022, with the possibility for extension, will report further on the activity of pembrolizumab in Hodgkin lymphoma, microsatellite instability-high tumours, and melanoma. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019. PMID: 31812554. doi:10.1016/S1470-2045(19)30671-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。